ER+ HER2- metastatic Breast Cancer (mBC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The majority of MBC-related mortality occurs in patients with hormone receptor (HR) positive, HER2 negative illness. Endocrine therapy (ET) is still the mainstay of treatment in these cases because it improves survival and quality of life. When all subtypes are taken into account, female breast cancer is fairly common. In 2022, there are expected to be 287,850 new cases of breast cancer in women. According to data from 2015 to 2019, the most common subtype of breast cancer is HR+/HER2-, with an age-adjusted incidence of 87.4 new cases per 100,000 women. While the HER2 receptor is absent in the majority of breast cancers, the estrogen receptor (ER) receptor is expressed. Hormone-based therapies are applied to the adjuvant setting to treat ER/HER2 cancers. The estrogen receptor (ER) receptor is expressed in the majority of breast cancers, whereas the HER2 receptor is not. Hormone-based therapies for ER/HER2 cancers are applied in the adjuvant setting. These treatments significantly increase survival rates in the context of metastatic disease.

Description

Patients with hormone receptor (HR)-positive and HER2-negative disease experience most of the mortality associated with MBC. In these cases, endocrine therapy (ET) remains essential for treatment that increases survival and quality of life. However, natural or acquired hormonal resistance can reduce the drug's effectiveness. Research into the causes of ET resistance has led to the development of a new spectrum of targeted drugs for advanced breast cancer. Combination with cyclin-dependent kinase (CDK) 4/6 inhibitors, selective estrogen receptor modulators, aromatase inhibitors, and/or selective estrogen receptor inhibitors, in addition to antiestrogen therapy, in primary and secondary settings. Although the PI3K/AKT/mTOR pathway is known to be an important growth pathway in HR-positive breast cancer, PI3K inhibitors have been disappointed due to small effect sizes and high levels of toxicity. The mTOR inhibitor Everolimus dramatically increases progression-free survival when used with ET, and recent studies have shown reduced toxicity and improved maintenance. Although outcomes are better with these multi-targeted therapies and chemotherapy is often delayed, long-term survival statistics are lacking, and the best sequencing of these drugs remains unknown.

ER+ HER2- metastatic Breast Cancer (mBC) (Epidemiology)

If all subtypes are taken into account, female breast cancer is quite common. In 2022, there are expected to be 287,850 new cases of female breast cancer. According to data from 2015 to 2019, HR+/HER2-related breast cancer has the highest age-adjusted incidence, with 87.4 new cases per 100,000 women. This rate is more than six times higher than the rates of HR-/Her2- and HR+/HER2- breast cancer, which are 13.2 and 12.9, respectively, and almost 16 times higher than the rate of 5.2 for those with these two subtypes of the disease. All prices are age-adjusted.

ER+ HER2- metastatic Breast Cancer (mBC) -Current Market Size & Forecast Trends

The market for ER+ HER2- metastatic breast cancer (mBC) is projected to experience substantial growth, with estimates indicating a market size of approximately USD 7.4 billion in 2022 across the G7 markets, which includes the US, EU5, and Japan. This segment is expected to see continued expansion, driven by advancements in targeted therapies and increased awareness of treatment options tailored for this specific subtype of breast cancer. The growth for ER+ HER2- mBC is supported by ongoing research and development efforts focusing on innovative therapies that target hormone receptor pathways, as well as improvements in patient management strategies. As the market evolves, it is expected to reach around USD 12 billion by 2035, further emphasizing the increasing demand for effective treatments in this patient population.

While the HER2 receptor is absent in the majority of breast cancers, the estrogen receptor (ER) receptor is expressed. Hormone-based therapies are used to treat ER/HER2 cancers in an adjuvant setting. These treatments considerably increase survival rates in the metastatic setting.

Hormone resistance is, however, a common symptom in metastatic patients.

The biology of ER/HER2 breast cancers has been better understood, leading to the development of new therapies for this disease, including CDK4/6 inhibitors and PI3K inhibitors. To address cancer vulnerabilities, novel drugs in clinical development target additional neoplastic processes. These include more recent techniques for ER blockade and HER2 receptor targeting in ER/HER2 cancers that express HER2 at low levels but do not meet the standards for clinical positivity. Additional promising therapeutic options include focusing on additional surface receptors or their downstream pathways, as well as the apoptotic apparatus and boosting the immune response, which is insufficient at first in these cancers.

Report Highlights

ER+ HER2- metastatic Breast Cancer (mBC) - Current Market Trends

ER+ HER2- metastatic Breast Cancer (mBC) - Current & Forecasted Cases across the G8 Countries

ER+ HER2- metastatic Breast Cancer (mBC) - Market Opportunities and Sales Potential for Agents

ER+ HER2- metastatic Breast Cancer (mBC) - Patient-based Market Forecast to 2035

ER+ HER2- metastatic Breast Cancer (mBC) - Untapped Business Opportunities

ER+ HER2- metastatic Breast Cancer (mBC) - Product Positioning Vis-a-vis Competitors' Products

ER+ HER2- metastatic Breast Cancer (mBC) - KOLs Insight